Metabolic surgery for non-obese type 2 diabetes: Incretins, adipocytokines, and insulin secretion/resistance changes in a 1-year interventional clinical controlled study

Annals of Surgery

Volumn 256, Issue 1, 2012, Pages 72-78

  Geloneze, Bruno ^a   Geloneze, Sylka Rodovalho ^a   Chaim, Elinton ^a   Hirsch, Fernanda Filgueira ^a   Felici, Ana Claudia ^a   Lambert, Giselle ^a   Tambascia, Marcos Antonio ^a   Pareja, José Carlos ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; LEPTIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; AUTOIMMUNITY; BODY MASS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETIC PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; DIET RESTRICTION; DIET THERAPY; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; DUODENAL JEJUNAL BYPASS; ENDOCRINE FUNCTION; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; INTESTINE BYPASS; MALE; MEAL; MEDICAL CARE; METABOLIC RATE; MIXED MEAL TOLERANCE TEST; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DIPEPTIDYL PEPTIDASE 4; DUODENUM; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HOMEOSTASIS; HUMANS; INCRETINS; INSULIN RESISTANCE; JEJUNUM; MIDDLE AGED;

EID: 84863304937     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182592c62     Document Type: Article

References (33)

1. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med. 2007;24:451-463.
2. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin dependent diabetes mellitus: problems and prospects. Endocr Rev. 1998;19:477-490.
3. Ferrannini E, Camastra S, Gastaldelli A, et al. Beta-cell function in obesity: effects of weight loss. Diabetes. 2004;53(suppl 3):S26-S33.
4. Donath MY, Schumann DM, Faulenbach M, et al. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care. 2008;31(suppl 2):S161-S164.
5. Gastaldelli A, Miyazaki Y, Pettiti M, et al. Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. J Clin Endocrinol Metab. 2004;89:3914-3921.
6. Hare KJ, Vilsbøll T, Asmar M, et al. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes. 2010;59:1765-1770.
7. Knop F,Vilsboll T,Hojberg PV, et al. Reduced incretin effect in type 2 diabetes. Cause or consequence of the diabetic state? Diabetes. 2007;56:1951-1959.
8. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004;89:2608-2615.
9. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724-1737.
10. Guidone C, Manco M, Valera-Mora E, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006;55:2025-2031.
11. de Carvalho CP, Marin DM, de Souza AL, et al. GLP-1 and adiponectin: effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal and abnormal glucose metabolism. Obes Surg. 2009;19:313-320.
12. Laferr̀ere B, Teixeira J,McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479-2485.
13. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a nonobese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239:1-11.
14. Pacheco D, de Luis DA, Romero A, et al. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg. 2007;194:221-224.
15. Cohen RV, Schiavon CA, Pinheiro JS, et al. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2: a report of 2 cases. Surg Obes Relat Dis. 2007;3:195-197.
16. Ramos AC, Galṽao Neto MP, de Souza YM, et al. Laparoscopic duodenaljejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI<30 kg/m2 (LBMI). Obes Surg. 2009;19:307-311.
17. Geloneze B, Geloneze SR, Fiori C, et al. Surgery for nonobese type 2 diabetic patients: an interventional study with duodenal-jejunal exclusion. Obes Surg. 2009;19:1077-1083.
18. Malerbi D, Damiani D, Rassi N, et al. Brazilian Diabetes Society consensus statement-intensive insulin therapy and insulin pump therapy. Arq Bras Endocrinol Metabol. 2006;50:125-135.
19. Nathan DM, Buse JB, Davisdon MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-1972.
20. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-1470.
21. Stumvoll M, Mitrakou A, PimentaW, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care. 2000;23:295-301.
22. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
23. Hovorka R, Chassin L, Luzio SD, et al. Pancreatic β-cell responsiveness during meal tolerance test: model assessment in normal subjects and subjects with newly diagnosed noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1998;83:744-750.
24. Retnakaran R, Qi Y, Goran MI, et al. Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med. 2009;26:1198-1203.
25. Rubino F, Forgione A, Cummings D, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741-749.
26. Shen S, Hanley AJ, Vuksan V, et al. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity. 2008;16:1901-1907.
27. Morioka T, Asilmaz E, Hu J, et al. Disruption of leptin receptor expression in the pancreas directly affects beta cell growth and function in mice. J Clin Invest. 2007;117:2860-2868.
28. Ducroc R, Guilmeau S, Akasbi K, et al. Luminal leptin induces rapid inhibition of active intestinal absorption of glucose mediated by sodium-glucose cotransporter 1. Diabetes. 2005;54:348-354.
29. Geloneze B, TambasciaMA, Pareja JC, et al. Serum leptin levels after bariatric surgery across a range of glucose tolerance from normal to diabetes. Obes Surg. 2001;11:693-698.
30. Inigo C, Patel N, Kellett GL, et al. Luminal leptin inhibits intestinal sugar absorption in vivo. Acta Physiol. 2007;190:303-310.
31. Moens K, Heimberg H, Flamez D, et al. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes. 1996;45:257-261.
32. Singh SK, Bartoo AC, Krishnan S, et al. Glucose-dependent insulinotropic polypeptide (GIP) stimulates transepithelial glucose transport. Obesity. 2008;16:2412-2416.
33. Moriya R, Shirakura T, Ito J, et al. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab. 2009;297:E1358-E1365.